Quarterly report
Open the filing on sec.gov
Metagenomi Therapeutics, Inc. (MGX)
Nasdaq: MGX · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2019
The companyfiscal 2025, as filed
Revenue$25.2M-51.8%
Net income-$87.9M-12.6%
Earnings per share$-2.360.0%
Operating cash flow-$88.9M+18.5%
Cash$46.9M+43.8%
Debtn/a
Shareholders’ equity$159M-32.5%
Shares, diluted37.3M+12.8%
Return on equity-55.4%
The recordfrom its filings
Filings in 202633
Newest filingNov 10 · 10-Q
Annual reportMar 5, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted8
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$94.2MCash from operations -$83.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.